Bristol-Myers Squibb: Finally Trending Up
JHVEPhoto After a period in purgatory, Bristol-Myers Squibb Company (NYSE:BMY) finally returned back into growth mode, though relatively slow. The biopharma has faced a period of excruciating LOEs on key drugs like Revlimid pressuring sales. My investment thesis remains Bullish on the biopharma stock, even after a solid bounce off the lows. Source: Finviz Turnaround Quarter Bristol-Myers just reported a quarter where sales actually returned to growth after a period of 5 quarters with sales dipping YoY. For ...